Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF, page-340

Each individual must make up their own mind as to the risk/reward with MSB, and most bought in due to the COVID ARDS and/or Ryoncil at a premium and have little knowledge or interest in the other indications. Both of which have had set backs, but in my opinion have not run their full cycle yet... but there lies the problem, it will take more time before we find out what will come of these.

Risk profile has definitely changed for the worst recently and I'm not surprised by analysts downgrading... reality is that the goal posts have in fact shifted out with sunny skies now somewhat clouded making it harder for many to see what potential lies ahead. But the potential is definitely still there IMO. Having said that, the market has priced in the additional risk with the market cap essentially taking a 50% discount to the recent highs. CLBP will determine the next big move up or down. Market is now jostling for position before that news is released .. which is due shortly.